Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)

NCT02428686

Myelodysplastic Syndromes

COMPLETED PHASE2

Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy

NCT02860598

Anemia Acute Myeloid Leukemia

UNKNOWN

Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant

NCT00815867

Kidney Failure

COMPLETED PHASE3

Correction of Anaemia and Progression of Renal Failure on Transplanted Patients

NCT00396435

Anaemia Renal Transplantation Kidney Failure

COMPLETED PHASE4

A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.

NCT00440063

Anemia

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. Thus, only 50-60% of patients with multiple myeloma or non-Hodgkin lymphoma respond to ESAs. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndromes Anemia Hemopathies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18
* patients with non-myeloid haemopathy receiving chemotherapy or myelodysplastic syndrome
* indication of ESAs therapy with Hb \< 11g/dl

Exclusion Criteria

* uncontrolled hypertension
* anemia due to deficiency
* pregnant and lactating women
* patient who received treatment with erythropoiesis-activating factors in the two months preceding inclusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No